Treatment Trial for Acute Central Serous Chorioretinopathy (NCT02784665) | Clinical Trial Compass
CompletedNot Applicable
Treatment Trial for Acute Central Serous Chorioretinopathy
China110 participantsStarted 2016-04
Plain-language summary
Central serous chorioretinopathy (CSC) is a relatively frequent eye disease in younger patients. It is characterized by serous detachment of the neurosensory retina with or without serous detachment of the retinal pigment epithelium (RPE), which can cause vision drop, image distortion, loss of color and contrast vision. Although nonfoveal focal leakage can be treated with traditional laser photocoagulation, but it has the side effects of causing RPE atrophy, scotoma, or secondary CNV. Photodynamic therapy (PDT) is another effective treatment but it's more than most families can afford to pay because of the high cost, what's more, it is accompanied with side-effects, such as choroidal ischemia, retinal pigmental epithelium (RPE) atrophy and RPE rip.
To date there is no international consensus on the optimal treatment of CSC Many retrospective studies suggest that micropulse laser (MPL) therapy may also be effective without obvious complications in this disease.
The purpose of this study is to evaluate the effect of micropulse laser (MPL) on acute central serous chorioretinopathy compared with the traditional laser coagulation.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. onset for the first time, as an episode duration of less than 6 months
✓. patient was between 18 and 55 years of age
✓. the presence of subretinal fluid(SRF) involving the macula and detected by use of optical coherence tomography (OCT)
✓. active fluorescein leakage during fluorescein angiography (FA)
✓. best corrected visual acuity (BCVA) more than 0.1, and less than 1.0
Exclusion criteria
✕. previous PDT, focal photocoagulation, intravitreal injections of anti-vascular endothelial growth factor, or ocular surgery
✕. other macular abnormalities such as choroidal neovascularization(CNV) or polypoidal choroidal vasculopathy(PCV)
✕. retinal atrophy
✕. pregnancy
✕. inability to obtain photographs or to perform FA
What they're measuring
1
the proportion of eyes with complete absorption of subretinal fluid (SRF)